309 related articles for article (PubMed ID: 30223804)
41. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.
Moritz S; Hünsche A; Lincoln TM
Eur Neuropsychopharmacol; 2014 Nov; 24(11):1745-52. PubMed ID: 25444234
[TBL] [Abstract][Full Text] [Related]
42. Subjective Medication Satisfaction With Antipsychotic Polypharmacy in a Naturalistic Inpatient and Outpatient Sample.
Kikkert MJ; de Mooij L; de Koning M; Dekker J
J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936243
[No Abstract] [Full Text] [Related]
43. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
Patel MX; De Zoysa N; Bernadt M; David A
J Psychopharmacol; 2009 Sep; 23(7):789-96. PubMed ID: 18583438
[TBL] [Abstract][Full Text] [Related]
44. Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?
Archie SM; Goldberg JO; Akhtar-Danesh N; Landeen J; McColl L; McNiven J
Psychiatr Serv; 2007 Feb; 58(2):233-9. PubMed ID: 17287381
[TBL] [Abstract][Full Text] [Related]
45. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
46. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
[TBL] [Abstract][Full Text] [Related]
47. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication.
Rettenbacher MA; Hofer A; Eder U; Hummer M; Kemmler G; Weiss EM; Fleischhacker WW
J Clin Psychiatry; 2004 Sep; 65(9):1211-8. PubMed ID: 15367047
[TBL] [Abstract][Full Text] [Related]
48. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
Kao YC; Liu YP
Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
[TBL] [Abstract][Full Text] [Related]
49. [Non-extrapyramidal motor side-effects in long-term therapy with neuroleptics: an analysis of 99 patients].
Ginzel I; Hilger E; Barnas C
Wien Klin Wochenschr; 2002 Jan; 114(1-2):38-43. PubMed ID: 12407934
[TBL] [Abstract][Full Text] [Related]
50. The impact of self-stigmatization on medication attitude in schizophrenia patients.
Feldhaus T; Falke S; von Gruchalla L; Maisch B; Uhlmann C; Bock E; Lencer R
Psychiatry Res; 2018 Mar; 261():391-399. PubMed ID: 29353769
[TBL] [Abstract][Full Text] [Related]
51. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
[TBL] [Abstract][Full Text] [Related]
52. Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia.
Patterson TL; Lacro J; McKibbin CL; Moscona S; Hughs T; Jeste DV
J Clin Psychopharmacol; 2002 Feb; 22(1):11-9. PubMed ID: 11799337
[TBL] [Abstract][Full Text] [Related]
53. Spirituality and religion in outpatients with schizophrenia: a multi-site comparative study of Switzerland, Canada, and the United States.
Mohr S; Borras L; Nolan J; Gillieron C; Brandt PY; Eytan A; Leclerc C; Perroud N; Whetten K; Pieper C; Koenig HG; Huguelet P
Int J Psychiatry Med; 2012; 44(1):29-52. PubMed ID: 23356092
[TBL] [Abstract][Full Text] [Related]
54. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Smith RC; Leucht S; Davis JM
Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
[TBL] [Abstract][Full Text] [Related]
55. Detection of non-adherent behaviour in early psychosis.
Hui CL; Chen EY; Kan CS; Yip KC; Law CW; Chiu CP
Aust N Z J Psychiatry; 2006 May; 40(5):446-51. PubMed ID: 16683971
[TBL] [Abstract][Full Text] [Related]
56. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
[TBL] [Abstract][Full Text] [Related]
57. [Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients].
Jalenques I; Ortega V; Legrand G; Auclair C
Encephale; 2016 Apr; 42(2):124-9. PubMed ID: 26796558
[TBL] [Abstract][Full Text] [Related]
58. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
59. The impact of negative treatment experiences on persistent refusal of antipsychotics.
Lincoln TM; Jung E; Wiesjahn M; Wendt H; Bock T; Schlier B
Compr Psychiatry; 2016 Oct; 70():165-73. PubMed ID: 27552661
[TBL] [Abstract][Full Text] [Related]
60. The impact of weight gain on quality of life among persons with schizophrenia.
Allison DB; Mackell JA; McDonnell DD
Psychiatr Serv; 2003 Apr; 54(4):565-7. PubMed ID: 12663847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
